Abstract 1124
Background
We previously showed that therapy with anti-CTLA-4 or anti-PD-1 agents was more effective for men as compared with women. Here we investigated whether women derive larger benefit than men from different immunotherapeutic strategies.
Methods
We performed a systematic review and a meta-analysis, including all RCTs testing anti-PD-1 or anti-PD-L1 given either alone or combined with chemotherapy in patients with advanced/metastatic solid tumors, to assess different efficacy of these two immunotherapeutic strategies according to patients’ sex. The primary endpoint of the study was to assess the difference of treatments efficacy between males and females, measured in terms of difference of the overall survival log(HR) reported in males and in females for each treatment strategy For this purpose, the pooled OS HR and 95% confidence interval (CI) was calculated in males and females using random-effects model and the heterogeneity between the two estimates was evaluated using an interaction test.
Results
16 phase III RCTs testing anti-PD1 or anti-PD-L1 in monotherapy versus standard chemotherapy in 9291 patients with advanced solid tumors were included in the analysis. Two RCTs were performed in patients with melanoma, 8 in NSCLC, 2 in HNSCC, 2 in gastric cancer, and 1 each in kidney and urothelial cancer. In 15 out of 16 of such RCTs, men derived larger OS benefit than women. The pooled-OS HR was 0.73 (95% CI, 0.69-0.78) in men versus 0.86 (95% CI, 0.78-0.94) in women (heterogeneity-p=0.0079). 5 phase III RCTs testing the combination of chemotherapy plus anti-PD-1 or anti-PD-L1 versus chemotherapy in 2979 patients were included in the analysis. Four RCTs were performed in NSCLC and 1 in SCLC. All these 5 RCTs showed impressively larger OS benefit in women. The pooled-OS HR was 0.50 (95% CI, 0.41-0.60) in women versus 0.76 (95% CI, 0.66-0.87) in men (heterogeneity p = 0.0003).
Conclusions
We confirmed a large and significant interaction between patients’ sex and the efficacy of anti-PD-1/anti-PD-L1 drugs given in monotherapy or combined with chemotherapy. The direction of such interaction was the opposite for the two immunotherapeutic strategies: women derived impressively larger benefit from the addition of chemotherapy to anti-PD1/PD-L1 as compared with men.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabio Conforti.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract